Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEVR trial

European Heart Journal

Volumn 39, Issue 5, 2018, Pages 363-370

  Fitchett, David ^a   Butler, Javed ^b   Van De Borne, Philippe ^c   Zinman, Bernard ^d,e   Lachin, John M ^f   Wanner, Christoph ^g   Woerle, Hans J ^h   Hantel, Stefan ^h   George, Jyothis T ^h   Johansen, Odd Erik ⁱ   Inzucchi, Silvio E ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b STONY BROOK UNIVERSITY   (United States)

^c ERASME HOSPITAL   (Belgium)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ Boehringer Ingelheim Norway KS   (Norway)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cardiovascular disease; Heart failure; Hospitalization; Mortality; Type 2 diabetes

Indexed keywords

BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCOSIDE;

ADVERSE EVENT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85043391124     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx511     Document Type: Article

References (23)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34:29-34.
2. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29:1377-1385.
3. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, Wheatcroft SB, Sapsford RJ, Witte KK, Kearney MT. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 2013; 10: 330-336.
4. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation 2015; 132:923-931.
5. Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15:194-202.
6. Johansson I, Edner M, Dahlström U, Näsman P, Rydén L, Norhammar A. Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. Eur J Heart Fail 2014; 16:409-418.
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128.
8. VR trial. Eur Heart J 2016; 37:1526-1534.
9. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014; 13:102.
10. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008; 1:125-133.
11. Kalogeropoulos A, Psaty BM, Vasan RS, Georgiopoulou V, Smith AL, Smith NL, Kritchevsky SB, Wilson PW, Newman AB, Harris TB, Butler J. Validation of the health ABC heart failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail 2010; 3:495-502.
12. Beyersmann JAA, Schumacher M. Competing Risks and Multistate Models with R. New York: Springer; 2011.
13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-2200.
14. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315-2381.
15. Agarwal SK, Chambless LE, Ballantyne CM, Astor B, Bertoni AG, Chang PP, Folsom AR, He M, Hoogeveen RC, Ni H, Quibrera PM, Rosamond WD, Russel SD, Shahar E, Heiss G. Prediction of incident heart failure in general practice. The Atherosclerosis Risk in Communities (ARIC) Study. Circ Heart Fail 2012; 5: 422-429.
16. Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: a cross-sectional comparison with non-diabetic weight-matched controls. J Diabetes 2015; 7:779-790.
17. Nakai H, Takeuchi M, Nishikage T, Lang RM, Otsuji Y. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr 2009; 10:926-932.
18. Poulsen MK, Henriksen JE, Dahl J, Johansen A, Gerke O, Vach W, Haghfelt T, Hoilund-Carlsen PF, Beck-Nielsen H, Moller JE. Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. Circ. Cardiovasc. Imaging 2010; 3:24-31.
19. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70:776.
20. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644-657.
21. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016; 37:3192-3200.
22. Verma S, McMurray JJV, Cherney DZI The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2017; 2:939-940.
23. Swedberg K, Rydén L. Treatment of diabetes and heart failure: joint forces. Eur Heart J 2016; 37:1535-1537.